NGeneBio Amends Share Allocation Ratio for Rights Offering, Core Terms Unchanged
NGeneBio filed an amendment to its rights offering decision on July 16, 2026, adjusting the new share allocation ratio from 0.8000820895 to 0.8008047920 per existing share.
This adjustment reflects minor changes in outstanding shares due to warrant exercises or treasury stock, with no impact on the total shares offered at 7.15 million or the pricing methodology.
The capital raise remains sizable at approximately 31% of the current market cap, posing significant dilution risk for existing shareholders who must subscribe or sell rights to protect their value.
[AI Summary]This amendment is purely administrative with no new financial risk, but the underlying capital increase continues to carry heavy dilution. Existing shareholders should act on the 0.8-to-1 subscription ratio or consider selling their rights to mitigate dilution.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)